Dr. Pilewski is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
MUH NW 628
3459 Fifth Avenue
Pittsburgh, PA 15213Phone+1 412-692-2164Fax+1 412-692-2260
Summary
- Joseph Pilewski, MD, is a pulmonologist based in Pittsburgh, PA, with subspecialties in cystic fibrosis, lung transplantation medicine, and general pulmonology. He completed his residency and fellowship at the University of Pennsylvania Health System following his medical education at the University of Rochester. Dr. Pilewski holds several employment positions, including a Staff Physician at UPMC Presbyterian Shadyside, UPMC East and UPMC Mercy, and is Professor of Medicine, Pediatrics, and Clinical and Translational Research at the University of Pittsburgh. He has served in several research and administrative capacities for the Cystic Fibrosis Foundation, and contributed significantly to research in Cystic Fibrosis and Lung Transplantation. He has been part of several clinical trials primarily serving as a site investigator.
Education & Training
- University of Pennsylvania Health SystemFellowship, Pulmonary Disease and Critical Care Medicine, 1990 - 1994
- University of Pennsylvania Health SystemResidency, Internal Medicine, 1987 - 1990
- University of Rochester School of Medicine and DentistryClass of 1987
Certifications & Licensure
- PA State Medical License 1988 - 2024
- American Board of Internal Medicine Critical Care Medicine
- American Board of Internal Medicine Pulmonary Disease
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011
Clinical Trials
- Inhaled Bicarbonate Therapy in Cystic Fibrosis Start of enrollment: 2002 Mar 01
- Mechanisms of Immune Tolerance and Inflammation in Patients With Cystic Fibrosis With ABPA Start of enrollment: 2005 Mar 01
- Open-label Vitamin D Trial for Patients With Cystic Fibrosis and Allergic Bronchopulmonary Aspergillosis Start of enrollment: 2010 Sep 01
- Join now to see all
Publications & Presentations
PubMed
- 1 citationsNasal Epithelium Transcriptomics Predict Clinical Response to Elexacaftor/Tezacaftor/Ivacaftor.Molin Yue, Daniel J Weiner, Kristina M Gaietto, Franziska J Rosser, Christopher M Qoyawayma
American Journal of Respiratory Cell and Molecular Biology. 2024-12-01 - IL-10 Is Critical for Regulation of Cytotoxic CD4+NKG7+ T Cells in Lung Allograft Rejection but Is Not Required for Allograft Acceptance.Antu Das, Xingan Wang, Kaitlyn Devonshire, Emily J Lyons, Iulia Popescu
Journal of Immunology. 2024-09-15 - 6 citationsIncidence of Acute Cellular Rejection After Granulocyte Colony-Stimulating Factor in Lung Transplant Recipients.Stacy R Fredrick, Carlo J Iasella, Lauren M Sacha, Ryan M Rivosecchi, Matthew R Morrell
Journal of Pharmacy Practice. 2024-08-01
Journal Articles
- Staphylococcus Aureus Biofilm Growth on Cystic Fibrosis Airway Epithelial Cells Is Enhanced During Respiratory Syncytial Virus CoinfectionMichael M Myerburg, Joseph M Pilewski, Brian R Kocak, mBio
Press Mentions
- CFF Strives to Improve Lung Transplant Journey for Cystic Fibrosis PatientsDecember 2nd, 2019
- To Save a Young Woman Besieged by Superbugs, Scientists Hunt a Killer VirusNovember 10th, 2017
- A Cystic Fibrosis Treatment Is Called ‘Game-Changing’May 7th, 2012
Grant Support
- Clinical/Biostatistics CoreNational Heart, Lung, And Blood Institute2009–2010
- Clinical/Biostatistics CoreNational Heart, Lung, And Blood Institute2006–2008
- A Multicenter, Double-Blind, Placebo-Controlled, Phase II Study Of AerosolizedNational Center For Research Resources2005
- Exhaled Carbon Monoxide As A Clinical Tool In CFNational Center For Research Resources2004–2005
- Core--Human Airway Cell And TissueNational Institute Of Diabetes And Digestive And Kidney Diseases1999–2002
- Aminoglycoside To Correct Cellular Defect In CF Airways Epithelia MutationsNational Center For Research Resources1999
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: